Monica L. Guzman   Assistant Professor of Pharmacology in Medicine

Cancer stem cells (CSCs) are thought to initate and perpetuate several malignancies including acute myelogenous leukemia (AML) and breast cancer. Recent evidence has shown that cancer stem cells (CSCs) represent a relatively quiescent subpopulation of cells that is refractory to current therapeutic treatments. Thus, it has been suggested that this population of CSCs may result in disease relapse. Therefore, CSCs represent a critical therapeutic target for improving clinical outcomes. Specifically, we have demonstrated that AML stem cells exist in a molecular state that is unique from their normal hematopoietic counterparts. Since these features are absent in normal cells, I successfully employed both molecular genetic and small molecule strategies that exploit these differences to selectively ablate AML at the bulk, stem, and progenitor level, with no appreciable toxicity to their normal hematopoietic counterparts.

For more information visit our website.


Sort by

Selected publications


Sort by

Select federal grants awarded

  • A Role for Elevated Autophagy in Survival and Chemoresistance of Leukemia Stem Cells  awarded by National Cancer Institute Principal Investigator 2012 - 2014
  • Identification of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem Cells during Remission  awarded by National Institutes of Health, Office of the Director Principal Investigator 2010 -
  • Center on the Microenvironment and Metastasis  awarded by National Cancer Institute Key Personnel 2009 - 2014
  • Predictors of Response to HSP90i  awarded by National Cancer Institute Principal Investigator Subaward 2013 -
  • Pharmacological Modulation of Epigenetic Changes in AML  awarded by National Cancer Institute Principal Investigator Subaward 2013 -


Primary Affiliation

  • Weill Cornell Medical College, Cornell University


full name

  • Dr. Monica L Guzman

primary email